INS and type 2 diabetes mellitus: In phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT01856881) in patients with T2D, four weeks of AKR-001 treatment resulted in a reduced atherogenic lipid profile and improved insulin sensitivity with reduced plasma glucose, insulin, and HOMA-IR (129).